

QureTech Bio granted European patent for new class of antibacterials

March 11, 2025

QureTech Bio AB (“QureTech”), a biotechnology company focusing on infectious disease, today announced that the European Patent Office (EPO) has decided to grant a patent for GmPcides, a new class of synthetic antibacterials.

QureTech's GmPcides represents an innovative class of small molecule synthetic antibiotics that effectively targets drug-resistant bacteria, including MRSA, without any evidence of resistance development.

"We are pleased to receive this patent grant from the European Patent Office," stated Markus Thor, CEO of QureTech. "The patent ensures strong protection for GmPcides, which is crucial in our industry, and marks an important step in making our compounds available to patients in need of effective treatment of drug-resistant bacteria."

The European Patent Office (EPO) granted the patent application titled "Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving Gram-positive bacteria" on February 26, providing patent protection until 2041. The patent has been approved in China and is pending in the USA, India, and Japan.

Contact

Markus Thor, CEO

E-mail: markus.thor@quretech.com

Telephone: +46 70 644 99 91

Web: www.quretech.com

About QureTech Bio

QureTech Bio AB is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times' greatest health threats, antimicrobial resistance (AMR). The company's lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram-positive bacteria. QureTech is located in Umeå, Sweden.